NCT01838369View on ClinicalTrials.gov

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Smoldering Multiple Myeloma
Interventions
DRUG

BI-505

Trial Locations (1)

SE-22185

Department of Hemtaology, Skåne University Hospital, Lund

Sponsors
All Listed Sponsors
lead

BioInvent International AB

INDUSTRY

NCT01838369 - A Phase II Study of BI-505 in Smoldering Multiple Myeloma | Biotech Hunter | Biotech Hunter